Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : North American Vaccine -- Ignore unavailable to you. Want to Upgrade?

To: Rick Strange who wrote (277)	2/11/1998 4:09:00 PM
From: Don W Stone	Read Replies (1) \| Respond to of 507

Rick: Your words are always very informing. If that is how one arrives at a reason to short NVX I would definitely take the contrarian view. As to NVX and the potential earnings for '98, '99 and thereafter I can tell you that I'll rely on the Goldman Sachs analyst and the UBS Securities analyst for my input. As to being short I'd say the RISK can in no way be justified. I am sure you are not short NVX at this time. I'll start adding that argument to my reasons to be long NVX. BASED ON THE EXTREMELY HIGH SHORT INTEREST IN NVX ONE SHOULD TAKE A CONTRARIAN POSITION AND GO LONG NVX AT THIS LEVEL. The short interest is about 4 million shares, about 100 days to cover, and the float is about 12 million shares of which at least 11 million is held by institutions. All the longs have to do is sit and wait. Something good will indeed happen that will drive the stock up and start a "short squeeze". Something as simple as the institutions just calling their stock could actually raise havoc for the shorts. :-} Now I'll go check out Zacks. I think you may have twisted up those eps numbers. I can say I know different. I am also assuming that you really do recognize that any estimate is condition on just when FDA approval happens although you don't give a clue by your comments that you understand that???????